(Q24318657)

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

GOA release 2020-03-11

1 reference

4

Gerald F Watts

0 references

Esther MM. Ooi

series ordinal

1

object named as

Esther M M Ooi

0 references

author name string

P Hugh R Barrett

series ordinal

2

0 references

Dick C Chan

series ordinal

3

0 references

language of work or name

English

0 references

publication date

May 2008

0 references

published in

Clinical Science

0 references

volume

114

0 references

page(s)

611-24

0 references

issue

10

0 references

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Nicotinic acid receptor subtypes and their ligands

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

The hypotriglyceridemic effect of eicosapentaenoic acid in rats is reflected in increased mitochondrial fatty acid oxidation followed by diminished lipogenesis

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Metabolism of apolipoprotein C-III in normolipemic human subjects

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus Relationships with lipids, apolipoproteins, and premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Postprandial distribution of apolipoproteins C-II and C-III in normal subjects and patients with mild hypertriglyceridemia: comparison of meals containing corn oil and medium-chain triglyceride oil.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Identification of a nuclear receptor that is activated by farnesol metabolites

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Lack of association between genetic variations of apo A-I–C-III–A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Kinetics of plasma apolipoprotein C-III as a determinant of diet-induced changes in plasma triglyceride levels

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Fat ingestion is associated with increased levels of apoC-III- and apoE-B-containing lipoprotein particles in humans.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Effects of nicotinic acid on concentrations of serum apolipoproteins B, C-I, C-II, C-III and E in hyperlipidemic patients

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

A mouse model with features of familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Human apolipoprotein A-I--C-III gene complex is located on chromosome 11

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Statin trials and goals of cholesterol-lowering therapy

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Triglycerides and the Risk of Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

ApoC-III gene polymorphisms and risk of coronary artery disease.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensit

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Peroxisome proliferator-activated receptors: from genes to physiology

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Omega-3 Ethyl Ester Concentrate Decreases Total Apolipoprotein CIII and Increases Antithrombin III in Postmyocardial Infarction Patients

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides

1 reference

https://api.crossref.org/works/10.1042%2FCS20070308

7 January 2021

Identifiers

DOI

10.1042/CS20070308

1 reference

Consolidated OpenCitations Corpus – April 2017

release_5xxisxotavhgnfujqew25j7xfe

1808641

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5xxisxotavhgnfujqew25j7xfe

24 November 2022

mapped directly with Wikidata item

1808641

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference